{"id":391267,"date":"2015-10-30T00:00:00","date_gmt":"2015-10-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu1015-biopharma-gram-negative-infections-in-the-cost-constrained-physician-payer-forum-eu5-2015\/"},"modified":"2026-04-22T17:29:39","modified_gmt":"2026-04-22T17:29:39","slug":"pforeu1015-biopharma-gram-negative-infections-in-the-cost-constrained-physician-payer-forum-eu5-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu1015-biopharma-gram-negative-infections-in-the-cost-constrained-physician-payer-forum-eu5-2015\/","title":{"rendered":"Gram-Negative Infections in the Cost-Constrained | Physician &#038; Payer Forum | EU5 | 2015"},"content":{"rendered":"<p><em>Market Access Opportunities for Novel Therapies Targeting Multi-Drug-Resistant Pathogens<\/em> Hospital-treated Gram-negative infections (GNIs) are becoming increasingly difficult to treat given rising rates of infections caused by multi-drug resistant (MDR) pathogens. As a result, many GNIs can no longer be effectively treated with antibiotics previously considered to be the most potent agents (i.e., third-generation cephalosporins, fluoroquinolones, and carbapenems). Therefore, commercial opportunities exist for new agents that can help address the threat of drug-resistant Gram-negative pathogens (GNPs). Notably, emerging broad-spectrum antibiotics such as Merck\u2019s Zerbaxa (ceftolozane\/tazobactam) and Allergan\/AstraZeneca\u2019s Avycaz (ceftazidime\/avibactam) will provide therapeutic options for many of these difficult-to-treat infections, including those caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant GNPs. However, in highly cost-sensitive markets such as those found in the EU5, marketers of novel antibiotics will need to provide clear evidence of clinical improvements and\/or cost benefits over well-entrenched, generically available standard-of-care agents, to receive a favorable health technology assessment (HTA) and command premium pricing.<\/p>\n","protected":false},"template":"","class_list":["post-391267","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-infectious-disease","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391267\/revisions"}],"predecessor-version":[{"id":576923,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391267\/revisions\/576923"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}